Top

Published in:

01-08-2020 | Overweight | Letter to the Editor

A case for Tamoxifen with ovarian function suppression

Authors: Pallavi Kopparthy, Karen Daily

Published in: Breast Cancer Research and Treatment | Issue 1/2020

Excerpt

Adjuvant endocrine treatment for premenopausal hormone receptor-positive breast cancer has become increasingly nuanced. Sufficient evidence and thus consensus exists on the treatment of patients at both ends of the spectrum; the lowest risk have excellent outcomes with Tamoxifen (TAM) alone for 5 years, and the highest risk have incremental benefit with the escalation of care to GnRHa-based ovarian function suppression (OFS) concurrent with chemotherapy followed by an Aromatase Inhibitor (AI). We describe clinical scenarios in which the third option, TAM with OFS, remains our preferred approach. …

Regan MM, Fleming GF, Walley B et al (2019) Adjuvant systemic treatment of premenopausal women with hormone receptor-positive early breast cancer: lights and shadows. J Clin Oncol 37:862–866CrossRef

Pagani O, Francis PA, Fleming GF et al (2020) Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: results from TEXT and SOFT. J Clin Oncol 38:1293–1303CrossRef

Bellet M, Gray KP, Francis PA et al (2016) Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol 34:1584–1593CrossRef

Dignam JJ, Wieand K, Johnson KA et al (2003) Obesity, tamoxifen use, and outcomes in women with estrogen receptor-positive early-stage breast cancer. J Natl Cancer Inst 95:1467–1476CrossRef

Sestak I, Distler W, Forbes JF et al (2010) Effect of body mass index on recurrences in tamoxifen and anastrozole treated women: an exploratory analysis from the ATAC trial. J Clin Oncol 28:3411–3415CrossRef

Title: A case for Tamoxifen with ovarian function suppression
Authors: Pallavi Kopparthy
Karen Daily
Publication date: 01-08-2020
Publisher: Springer US
Keywords: Overweight
Tamoxifen
Cytostatic Therapy
Published in: Breast Cancer Research and Treatment / Issue 1/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05766-4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2020

Association between selenium intake and breast cancer risk: results from the Women’s Health Initiative

Use of MarginProbe as an adjunct to standard operating procedure does not significantly reduce re-excision rates in breast conserving surgery

Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer

Cardiovascular mortality and morbidity burden in successive and age pre-stratified case–control cohorts of breast cancer women. A population-based study

Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer

Standardize the management procedures for breast cancer patients during the outbreak of COVID-19 in Wuhan, China

Keynote webinar | Spotlight on antibody–drug conjugates in cancer